<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35787375</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>298</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>A quantitative high-throughput screen identifies compounds that lower expression of the SCA2-and ALS-associated gene ATXN2.</ArticleTitle><Pagination><StartPage>102228</StartPage><MedlinePgn>102228</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102228</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2022.102228</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(22)00670-6</ELocationID><Abstract><AbstractText>CAG repeat expansions in the ATXN2 (ataxin-2) gene can cause the autosomal dominant disorder spinocerebellar ataxia type 2 (SCA2) as well as increase the risk of ALS. Abnormal molecular, motor, and neurophysiological phenotypes in SCA2 mouse models are normalized by lowering ATXN2 transcription, and reduction of nonmutant Atxn2 expression has been shown to increase the life span of mice overexpressing the TDP-43 (transactive response DNA-binding protein 43 kDa) ALS protein, demonstrating the potential benefits of targeting ATXN2 transcription in humans. Here, we describe a quantitative high-throughput screen to identify compounds that lower ATXN2 transcription. We screened 428,759 compounds in a multiplexed assay using an ATXN2-luciferase reporter in human embryonic kidney 293 (HEK-293)&#xa0;cells and identified a diverse set of compounds capable of lowering ATXN2 transcription. We observed dose-dependent reductions of endogenous ATXN2 in HEK-293&#xa0;cells treated with procillaridin A,&#xa0;17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), and heat shock protein 990 (HSP990), known inhibitors of HSP90 and Na<sup>+</sup>/K<sup>+</sup>-ATPases. Furthermore, HEK-293&#xa0;cells expressing polyglutamine-expanded ATXN2-Q58 treated with 17-DMAG had minimally detectable ATXN2, as well as normalized markers of autophagy and endoplasmic reticulum stress, including STAU1 (Staufen 1), molecular target of rapamycin, p62, LC3-II (microtubule-associated protein 1A/1B-light chain 3II), CHOP (C/EBP homologous protein), and phospho-eIF2&#x3b1; (eukaryotic initiation factor 2&#x3b1;). Finally, bacterial artificial chromosome ATXN2-Q22 mice treated with 17-DMAG or HSP990 exhibited highly reduced ATXN2 protein abundance in the cerebellum. Taken together, our study demonstrates inhibition of HSP90 or Na<sup>+</sup>/K<sup>+</sup>-ATPases as potentially effective therapeutic strategies for treating SCA2 and ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scoles</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah, USA. Electronic address: Daniel.Scoles@hsc.utah.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandelman</LastName><ForeName>Mandi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Sharan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dexheimer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dansithong</LastName><ForeName>Warunee</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Karla P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pflieger</LastName><ForeName>Lance T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redlin</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kales</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hongmao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damoiseaux</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, and Department of Bioengineering in the Samueli School of Engineering, University of California Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simeonov</LastName><ForeName>Anton</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jadhav</LastName><ForeName>Ajit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulst</LastName><ForeName>Stefan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah, USA. Electronic address: Stefan.Pulst@hsc.utah.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 NS127253</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC4 NS073009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097903</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS103009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS033123</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS103883</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593752">ATXN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492185">STAU1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 7.2.2.13</RegistryNumber><NameOfSubstance UI="D000254">Sodium-Potassium-Exchanging ATPase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000254" MajorTopicYN="N">Sodium-Potassium-Exchanging ATPase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="Y">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">17-DMAG</Keyword><Keyword MajorTopicYN="N">HSP90</Keyword><Keyword MajorTopicYN="N">HSP990</Keyword><Keyword MajorTopicYN="N">NaK-ATPases</Keyword><Keyword MajorTopicYN="N">ataxin-2</Keyword><Keyword MajorTopicYN="N">cardiac glycoside</Keyword><Keyword MajorTopicYN="N">proscillaridin A</Keyword><Keyword MajorTopicYN="N">quantitative high-throughput screening</Keyword><Keyword MajorTopicYN="N">spinocerebellar ataxia type 2</Keyword></KeywordList><CoiStatement>Conflict of interest All works by T. D., D. M., and A. J. were performed during employment at the National Center for Advancing Translational Sciences. T. D. is now employed by The Frederick National Laboratory, D. M. by Veralox Therapeutics, Inc, and A. J. by Pfizer, Inc. All other authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>17</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35787375</ArticleId><ArticleId IdType="pmc">PMC9356275</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2022.102228</ArticleId><ArticleId IdType="pii">S0021-9258(22)00670-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Figueroa K.P., Pulst S.M. Identification and expression of the gene for human ataxin-2-related protein on chromosome 16. Exp. Neurol. 2003;184:669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">14769358</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez M., McClain M.E., Martinez R.A., Snow K., Lipe H., Ravits J., et al. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology. 2000;55:569&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">10953195</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulst S.M., Nechiporuk A., Nechiporuk T., Gispert S., Chen X.N., Lopes-Cendes I., et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 1996;14:269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G., Saudou F., Yvert G., Devys D., Trottier Y., Garnier J.M., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 1996;14:285&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanpei K., Takano H., Igarashi S., Sato T., Oyake M., Sasaki H., et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet. 1996;14:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U., Ralser M., Welzel F., Piccini I., Balzereit D., Yaspo M.L., et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol. Biol. Cell. 2007;18:1385&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata H., Huynh D.P., Pulst S.M. A&#xa0;novel protein with RNA-binding motifs interacts with ataxin-2. Hum. Mol. Genet. 2000;9:1303&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov G., Trempe J.F., Khaleghpour K., Kahvejian A., Ekiel I., Gehring K. Structure and function of the C-terminal PABC domain of human poly(A)-binding protein. Proc. Natl. Acad. Sci. U. S. A. 2001;98:4409&#x2013;4413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31848</ArticleId><ArticleId IdType="pubmed">11287632</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M.A., Soo K.Y., Warraich S.T., Sundaramoorthy V., Blair I.P., Atkin J.D. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:717&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">23172909</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Dansithong W., Figueroa K.P., Scoles D.R., Pulst S.M. Staufen1 links RNA stress granules and autophagy in a model of neurodegeneration. Nat. Commun. 2018;9:3648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128856</ArticleId><ArticleId IdType="pubmed">30194296</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Dansithong W., Gandelman M., Zu T., Ranum L.P., Figueroa K.P., et al. Staufen blocks autophagy in neurodegeneration. bioRxiv. 2019 doi: 10.1101/659649. preprint.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/659649</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansithong W., Paul S., Figueroa K.P., Rinehart M.D., Wiest S., Pflieger L.T., et al. Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406435</ArticleId><ArticleId IdType="pubmed">25902068</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Tang T.S., Tu H., Nelson O., Herndon E., Huynh D.P., et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J.&#xa0;Neurosci. 2009;29:9148&#x2013;9162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2749883</ArticleId><ArticleId IdType="pubmed">19625506</ArticleId></ArticleIdList></Reference><Reference><Citation>Saugstad J.A., Marino M.J., Folk J.A., Hepler J.R., Conn P.J. RGS4 inhibits signaling by group I metabotropic glutamate receptors. J.&#xa0;Neurosci. 1998;18:905&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792754</ArticleId><ArticleId IdType="pubmed">9437012</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Ghani M.A., Valiante T.A., Carlen P.L., Pennefather P.S. Metabotropic glutamate receptors coupled to IP3 production mediate inhibition of IAHP in rat dentate granule neurons. J.&#xa0;Neurophysiol. 1996;76:2691&#x2013;2700.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899638</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles D.R., Meera P., Schneider M.D., Paul S., Dansithong W., Figueroa K.P., et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.H., Chung T.D., Oldenburg K.R. A&#xa0;simple statistical parameter for use in evaluation and validation of high throughput screening assays. J.&#xa0;Biomol. Screen. 1999;4:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">10838414</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Southall N., Wang Y., Yasgar A., Shinn P., Jadhav A., et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 2011;3:80ps16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098042</ArticleId><ArticleId IdType="pubmed">21525397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews Griner L.A., Guha R., Shinn P., Young R.M., Keller J.M., Liu D., et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 2014;111:2349&#x2013;2354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926026</ArticleId><ArticleId IdType="pubmed">24469833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kijima T., Prince T.L., Tigue M.L., Yim K.H., Schwartz H., Beebe K., et al. HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation. Sci. Rep. 2018;8:6976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5934406</ArticleId><ArticleId IdType="pubmed">29725069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Guo Y., Guettouche T., Smith D.F., Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell. 1998;94:471&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">9727490</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Dansithong W., Figueroa K.P., Gandelman M., Scoles D.R., Pulst S.M. Staufen1 in human neurodegeneration. Ann. Neurol. 2021;89:1114&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">33745139</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuenschwander A.G., Thai K.K., Figueroa K.P., Pulst S.M. Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis. JAMA Neurol. 2014;71:1529&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939089</ArticleId><ArticleId IdType="pubmed">25285812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen S.T., Meera P., Otis T.S., Pulst S.M. Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum. Mol. Genet. 2013;22:271&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526159</ArticleId><ArticleId IdType="pubmed">23087021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M., Dansithong W., Figueroa K.P., Paul S., Scoles D.R., Pulst S.M. Staufen 1 amplifies proapoptotic activation of the unfolded protein response. Cell Death Differ. 2020;27:2942&#x2013;2951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492261</ArticleId><ArticleId IdType="pubmed">32415281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Bansal A., Hashimoto-Torii K. HSP70 and HSP90 in neurodegenerative diseases. Neurosci. Lett. 2020;716:134678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336893</ArticleId><ArticleId IdType="pubmed">31816334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Liu T., Rios Z., Mei Q., Lin X., Cao S. Heat shock proteins and cancer. Trends Pharmacol. Sci. 2017;38:226&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">28012700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubra K.T., Uddin M.A., Akhter M.S., Barabutis N. Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells. Cell Signal. 2020;67:109500.</Citation><ArticleIdList><ArticleId IdType="pubmed">31837463</ArticleId></ArticleIdList></Reference><Reference><Citation>Roue G., Perez-Galan P., Mozos A., Lopez-Guerra M., Xargay-Torrent S., Rosich L., et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in&#xa0;vitro and in&#xa0;vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood. 2011;117:1270&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">21106982</ArticleId></ArticleIdList></Reference><Reference><Citation>Buontempo F., Orsini E., Lonetti A., Cappellini A., Chiarini F., Evangelisti C., et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget. 2016;7:1323&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4811463</ArticleId><ArticleId IdType="pubmed">26593250</ArticleId></ArticleIdList></Reference><Reference><Citation>Winnicka K., Bielawski K., Bielawska A., Miltyk W. Dual effects of ouabain, digoxin and proscillaridin A on the regulation of apoptosis in human fibroblasts. Nat. Prod. Res. 2010;24:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">20140806</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyano S., Yagishita S., Tada M., Doi H., Uchihara T., Tanaka F. Parallel appearance of polyglutamine and transactivation-responsive DNA-binding protein 43 and their complementary subcellular localization in brains of patients with spinocerebellar ataxia type 2. J.&#xa0;Neuropathol. Exp. Neurol. 2022;81:535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">35511239</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang M.Y., Markmiller S., Vu A.Q., Javaherian A., Dowdle W.E., Jolivet P., et al. Small-molecule modulation of TDP-43 recruitment to stress granules prevents persistent TDP-43 accumulation in ALS/FTD. Neuron. 2019;103:802&#x2013;819.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728177</ArticleId><ArticleId IdType="pubmed">31272829</ArticleId></ArticleIdList></Reference><Reference><Citation>Skubnik J., Svobodova Pavlickova V., Psotova J., Rimpelova S. Cardiac glycosides as autophagy modulators. Cells. 2021;10:3341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8699753</ArticleId><ArticleId IdType="pubmed">34943848</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan J.R., Kolaitis R.M., Taylor J.P., Parker R. Eukaryotic stress granules are cleared by granulophagy and Cdc48/VCP function. Cell. 2013;153:1461&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760148</ArticleId><ArticleId IdType="pubmed">23791177</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellatyar H., Talaei S., Pilehvar-Soltanahmadi Y., Barzegar A., Akbarzadeh A., Shahabi A., et al. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: overview and current state of the art. Biomed. Pharmacother. 2018;102:608&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">29602128</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z.Y., Lu J., Zhao Y. A&#xa0;physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br. J. Pharmacol. 2014;171:2778&#x2013;2789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243854</ArticleId><ArticleId IdType="pubmed">24471734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.H., et al. In&#xa0;vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 2005;56:115&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15791458</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreafico A., Delord J.P., De Mattos-Arruda L., Berge Y., Rodon J., Cottura E., et al. A&#xa0;first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br. J. Cancer. 2015;112:650&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333497</ArticleId><ArticleId IdType="pubmed">25625276</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Fernandes A., Duarte-Silva S., Neves-Carvalho A., Amorim M., Soares-Cunha C., Oliveira P., et al. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics. 2014;11:433&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996110</ArticleId><ArticleId IdType="pubmed">24477711</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbst M., Wanker E.E. Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy. Neurodegener Dis. 2007;4:254&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17596719</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokui K., Adachi H., Waza M., Katsuno M., Minamiyama M., Doi H., et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 2009;18:898&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann-Stroissnigg H., Ling Y.Y., Zhao J., McGowan S.J., Zhu Y., Brooks R.W., et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun. 2017;8:422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5583353</ArticleId><ArticleId IdType="pubmed">28871086</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles D.R., Pflieger L.T., Thai K.K., Hansen S.T., Dansithong W., Pulst S.M. ETS1 regulates the expression of ATXN2. Hum. Mol. Genet. 2012;21:5048&#x2013;5065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490512</ArticleId><ArticleId IdType="pubmed">22914732</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarenkov V., Kevorkov D., Zentilli P., Gagarin A., Malo N., Nadon R. HTS-Corrector: software for the statistical analysis and correction of experimental high-throughput screening data. Bioinformatics. 2006;22:1408&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">16595559</ArticleId></ArticleIdList></Reference><Reference><Citation>Inglese J., Auld D.S., Jadhav A., Johnson R.L., Simeonov A., Yasgar A., et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U. S. A. 2006;103:11473&#x2013;11478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518803</ArticleId><ArticleId IdType="pubmed">16864780</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>